New drug aims to restore muscle protein in boys with DMD
Disease control
Recruiting now
This study tests a weekly intravenous drug, NS-089/NCNP-02, in 20 boys aged 4 to 14 with Duchenne muscular dystrophy (DMD) who have a specific genetic mutation. The goal is to help their bodies produce a missing muscle protein, dystrophin, to slow muscle damage. Participants must…
Phase: PHASE2 • Sponsor: NS Pharma, Inc. • Aim: Disease control
Last updated May 13, 2026 16:04 UTC